Cargando…

In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy

Chimeric antigen receptor-T (CAR-T) cell-based therapy has become a successful option for treatment of numerous hematological malignancies, but also raises hope in a range of non-malignant diseases. However, in a traditional approach, generation of CAR-T cells is associated with the separation of pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Śledź, Marta, Wojciechowska, Alicja, Zagożdżon, Radosław, Kaleta, Beata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329070/ https://www.ncbi.nlm.nih.gov/pubmed/37419996 http://dx.doi.org/10.1007/s00005-023-00683-y

Ejemplares similares

Correction to: In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy
por: Śledź, Marta, et al.
Publicado: (2023)

Immunomodulatory Properties of Polysaccharides from Lentinula edodes
por: Roszczyk, Aleksander, et al.
Publicado: (2022)

Regulatory T cells contribute to the immunosuppressive phenotype of neutrophils in a mouse model of chronic lymphocytic leukemia
por: Goral, Agnieszka, et al.
Publicado: (2023)

Osteopontin Gene Polymorphism and Urinary OPN Excretion in Patients with Immunoglobulin A Nephropathy
por: Kaleta, Beata, et al.
Publicado: (2019)

In Situ Programming of CAR T Cells
por: Parayath, Neha N., et al.
Publicado: (2021)

Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells
por: Zielniok, Katarzyna, et al.
Publicado: (2020)

Sildenafil Citrate Influences Production of TNF-α in Healthy Men Lymphocytes
por: Zych, Michał, et al.
Publicado: (2019)

Interleukin 12: still a promising candidate for tumor immunotherapy?
por: Lasek, Witold, et al.
Publicado: (2014)

Comparative Study of Immunomodulatory Agents to Induce Human T Regulatory (Treg) Cells: Preferential Treg-Stimulatory Effect of Prednisolone and Rapamycin
por: Janyst, Michał, et al.
Publicado: (2020)

Immune Evasion as the Main Challenge for Immunotherapy of Cancer
por: Zagozdzon, Radoslaw, et al.
Publicado: (2022)

Versatile CAR T-cells for cancer immunotherapy
por: Chu, Fuliang, et al.
Publicado: (2018)

Tuning the performance of CAR T cell immunotherapies
por: Richardson, Noah H., et al.
Publicado: (2019)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Identification of the Primary Structure of Selenium-Containing Polysaccharides Selectively Inhibiting T-Cell Proliferation
por: Klimaszewska, Marzenna, et al.
Publicado: (2021)

Selective Biological Effects of Selenium-Enriched Polysaccharide (Se-Le-30) Isolated from Lentinula edodes Mycelium on Human Immune Cells
por: Kaleta, Beata, et al.
Publicado: (2021)

The Effect of Novel Selenopolysaccharide Isolated from Lentinula edodes Mycelium on Human T Lymphocytes Activation, Proliferation, and Cytokines Synthesis
por: Roszczyk, Aleksander, et al.
Publicado: (2022)

Nanobody-based CAR-T cells for cancer immunotherapy
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)

Opportunities for CAR-T Cell Immunotherapy in HIV Cure
por: Campos-Gonzalez, Gerard, et al.
Publicado: (2023)

New cell sources for CAR-based immunotherapy
por: Mazinani, Marzieh, et al.
Publicado: (2023)

Cancer stem cells in haematological malignancies
por: Zagozdzon, Radoslaw, et al.
Publicado: (2015)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy
por: Calmeiro, João, et al.
Publicado: (2019)

Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy
por: Pellegrino, Marsha, et al.
Publicado: (2020)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
por: Ren, Anqi, et al.
Publicado: (2023)

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
por: Alvanou, Maria, et al.
Publicado: (2023)

Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
por: Hawkins, Elizabeth R, et al.
Publicado: (2021)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
por: Golubovskaya, Vita, et al.
Publicado: (2016)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

CAR-NK cells for cancer immunotherapy: from bench to bedside
por: Zhang, Leisheng, et al.
Publicado: (2022)

The role of MSCs and CAR-MSCs in cellular immunotherapy
por: Yan, Lun, et al.
Publicado: (2023)

CAR T-cell immunotherapy of B-cell malignancy: the story so far
por: Halim, Leena, et al.
Publicado: (2020)

Pressing Need at the Front for Mufflers
por: Penoyre, John
Publicado: (1917)

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases
por: Chen, Yuehong, et al.
Publicado: (2019)

CAR‐NK cell in cancer immunotherapy; A promising frontier
por: Marofi, Faroogh, et al.
Publicado: (2021)

Could Self-Reported Body Sizes Be an Alternative Tool for Assessing Breast Cancer Risk in Postmenopausal Women?
por: Świątkowska, Beata, et al.
Publicado: (2022)

Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
por: Arndt, Claudia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u1diot3h9g5piquetbpfl4c1j5